Cervical Cancer

A essay nominating Kimberly Spina, B.S.N., RN for CURE®’s Extraordinary Healer® Award, written by Stephanie Fraser, M.S.W., of The University of Vermont Cancer Center.

Here are the top 5 CURE stories for January 2019.

Nearly 90 percent of women experienced sexual dysfunction; however, providers were not openly communicating about this side effect, according to survey results.

In conjunction with Cervical Cancer Awareness Month, recognized in the month of January, here are some fast facts about the disease.

The Food and Drug Administration (FDA) approved an expanded age indication for GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), according to Merck, the manufacturer of the HPV vaccine.
 

Non-pharmacologic integrative medicine approaches such as aromatherapy and reflexology can dramatically reduce the pain and anxiety associated with cervical radiation therapy, according to a clinical study currently underway at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
 

The application is seeking approval for GARDASIL 9 to be used in women and men aged 27 to 45 years for the prevention of certain cancers and diseases caused by the nine human papillomavirus (HPV) types covered by the vaccine.

The Food and Drug Administration approved Keytruda (pembrolizumab) for the treatment of certain patients with cervical cancer.

Keytruda (pembrolizumab) was granted a priority review by the Food and Drug Administration (FDA) for the treatment of patients with advanced cervical cancer with disease progression or after chemotherapy.
 

Treatment of HIV has drastically improved since the 1980s, but many of these individuals are still facing barriers to proper cancer care.